oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors
Dept Womens & Childrens Hlth, Uppsala Univ, Uppsala, Sweden.
Örebro universitet, Institutionen för hälsovetenskap och medicin. Region Örebro län. Dept Obstet & Gynecol, Örebro University Hospital, Örebro, Sweden.
Dept Womens & Childrens Hlth, Uppsala Univ, Uppsala, Sweden..
Örebro universitet, Institutionen för läkarutbildning. Region Örebro län. Dept Obstet & Gynecol, Örebro University Hospital, Örebro, Sweden.
Vise andre og tillknytning
2014 (engelsk)Inngår i: Menopause: The Journal of the North American Menopause, ISSN 1072-3714, E-ISSN 1530-0374, Vol. 21, nr 4, s. 383-390Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: Women with breast cancer who are treated with aromatase inhibitors often experience vaginal atrophy symptoms and sexual dysfunction. This work aims to study proliferation and the presence and distribution of steroid hormone receptors in vaginal biopsies in relation to vaginal atrophy and vaginal pH in women with breast cancer who are on adjuvant endocrine treatment and in healthy postmenopausal women.

Methods: This is a cross-sectional study that compares postmenopausal aromatase inhibitor-treated women with breast cancer (n = 15) with tamoxifen-treated women with breast cancer (n = 16) and age-matched postmenopausal women without treatment (n = 19) or with vaginal estrogen therapy (n = 16). Immunohistochemistry was used to study proliferation and steroid hormone receptor staining intensity. Data was correlated with estrogen and androgen levels, vaginal atrophy scores, and vaginal pH.

Results: Aromatase inhibitor-treated women had a lower grade of proliferation, weaker progesterone receptor staining, and stronger androgen receptor staining, which correlated with plasma estrone levels, vaginal atrophy scores, and vaginal pH.

Conclusions: Women with aromatase inhibitor-treated breast cancer exhibit reduced proliferation and altered steroid hormone receptor staining intensity in the vagina, which are related to clinical signs of vaginal atrophy. Although these effects are most probably attributable to estrogen suppression, a possible local inhibition of aromatase cannot be ruled out.

sted, utgiver, år, opplag, sider
Lippincott Williams & Wilkins, 2014. Vol. 21, nr 4, s. 383-390
Emneord [en]
Aromatase inhibitors, Steroid hormone receptors, Vaginal atrophy
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-55187DOI: 10.1097/GME.0b013e31829e41dfISI: 000336214200012PubMedID: 24080848Scopus ID: 2-s2.0-84897538695OAI: oai:DiVA.org:oru-55187DiVA, id: diva2:1070613
Forskningsfinansiär
Swedish Cancer Society, CAN 2012/603
Merknad

Funding Agnecy:

Uppsala-Örebro Regional Research Council 

Lions Club International  

Percy Falk Foundation 

Tilgjengelig fra: 2017-02-01 Laget: 2017-02-01 Sist oppdatert: 2018-06-19bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Baumgart, JulianeNilsson, Kerstin

Søk i DiVA

Av forfatter/redaktør
Baumgart, JulianeNilsson, Kerstin
Av organisasjonen
I samme tidsskrift
Menopause: The Journal of the North American Menopause

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 176 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf